$7.87
+3.96%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$7.80
From 52W high−16.19%
Volume188469.00
Market cap$424.40M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$7.80
From 52W high
−16.19%
Volume
188469.00
Market cap
$424.40M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.2x
P/E (TTM)
—
RSI (14)
54.0
MomentumView details →
1D Return
+3.96%
YTD Return
−0.19%
SummaryUpdated Jun 1, 2026
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Minneapolis, Minnesota. The company was formerly known as DiaMedica Inc. before changing its name in December 2016. DiaMedica focuses on developing novel treatments for neurological and kidney diseases, with its lead drug candidate DM199 currently in Phase 2 and Phase 2/3 clinical trials for stroke and kidney disease applications. The company went public in 2012 and has since expanded its clinical pipeline to include treatments for preeclampsia, representing a significant pivot into pregnancy-related conditions.
Similar companies
Latest newsMore news →
DiaMedica Therapeutics rescheduled its virtual fetal growth restriction key opinion leader webinar to November 24, 2026, at 8:00 a.m. Eastern Time.11h agoDiaMedica Therapeutics announced it will host a virtual key opinion leader webinar on October 23, 2026 to discuss DM199 (rinvecalinase alfa) for fetal growth restriction, including early Phase 2 FGR results.19d agoDiaMedica Therapeutics reported its second-quarter progress and financial results, highlighting advancement of DM199 in early-onset fetal growth restriction, preeclampsia, and acute ischemic stroke, and a cash runway expected to extend through 2027.69d ago